The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy

IntroductionImmunoglobulin A nephropathy (IgAN) and membranous nephropathy (MN) are among the most common forms of primary glomerular diseases, with a rising global incidence. Despite their clinical importance, the underlying pathogenesis of these diseases and the development of reliable non-invasiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Lei Zhang, Lan Hu, Li Tan, Zhenjie Zhang, Mengying Chen, Wenbo Gan, Li Chen, Yan Zou, Shi Wang, Yu Pang, Zhenxin Fan, Junjie Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1618947/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850099438790377472
author Lei Zhang
Lan Hu
Lan Hu
Lan Hu
Li Tan
Zhenjie Zhang
Mengying Chen
Wenbo Gan
Li Chen
Yan Zou
Shi Wang
Yu Pang
Zhenxin Fan
Junjie Liu
author_facet Lei Zhang
Lan Hu
Lan Hu
Lan Hu
Li Tan
Zhenjie Zhang
Mengying Chen
Wenbo Gan
Li Chen
Yan Zou
Shi Wang
Yu Pang
Zhenxin Fan
Junjie Liu
author_sort Lei Zhang
collection DOAJ
description IntroductionImmunoglobulin A nephropathy (IgAN) and membranous nephropathy (MN) are among the most common forms of primary glomerular diseases, with a rising global incidence. Despite their clinical importance, the underlying pathogenesis of these diseases and the development of reliable non-invasive diagnostic tools remain inadequately understood. Accumulating evidence suggests that gut microbiota and its associated metabolites may play a crucial role in the development of kidney diseases via the gut-kidney axis. However, comprehensive studies integrating both microbiome and metabolomic data in IgAN and MN are still limited.MethodsIn this study, we performed integrated metagenomic sequencing and untargeted metabolomic profiling to investigate alterations in gut microbial composition and systemic metabolic changes associated with IgAN and MN. Fecal samples were collected from 24 patients with IgAN, 20 patients with MN, and 17 healthy controls. Microbial diversity and composition were assessed using metagenomic analysis, while metabolic profiles were evaluated through untargeted LC -MS-based metabolomics. Multivariate statistical analyses and biomarker modeling were employed to identify discriminative features and evaluate diagnostic performance. Microbiota-metabolite correlation networks were constructed to explore potential mechanistic links.ResultsMetagenomic analysis showed that both the IgAN and MN groups had significantly reduced α-diversity. Although β-diversity analysis did not reveal significant differences between the three groups, the IgAN and MN groups exhibited higher sample dispersion than the control group. Notably, both IgAN and MN patients showed a decrease in the abundance of certain specific microbial taxa. A total of 34 and 28 differentially abundant microbial species were identified in IgAN and MN, respectively, compared to healthy controls, with 16 taxa consistently downregulated in both disease groups. Notably, Streptococcus oralis was significantly enriched in the MN group, while [Clostridium] innocuum was markedly depleted. Metabolomic profiling identified 307 and 209 differentially abundant metabolites in IgAN and MN, respectively. Dipeptides (e.g., prolylleucine) were consistently upregulated, while the levels of certain short-chain fatty acids (SCFA) were reduced. Multivariate biomarker models demonstrated excellent diagnostic performance, achieving area under the curve (AUC) of 0.919 (IgAN vs. control), 0.897 (MN vs. control) and 0.912 (IgAN vs. MN), surpassing individual metabolite markers.DiscussionOur findings highlight significant alterations in gut microbial composition and systemic metabolite profiles in both IgAN and MN patients compared to healthy individuals. The consistent reduction in microbial diversity and SCFA-producing taxa, along with characteristic changes in metabolic signatures, supports the involvement of the gut-kidney axis in disease pathogenesis. The diagnostic models developed in this study provide promising non-invasive biomarkers for distinguishing IgAN and MN with high accuracy. These results contribute novel insights into the microbe-metabolite interplay in glomerular diseases and offer potential targets for future diagnostic and therapeutic strategies.
format Article
id doaj-art-653e22cb3e794261b13fd77cf32e0f8e
institution DOAJ
issn 2296-858X
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Medicine
spelling doaj-art-653e22cb3e794261b13fd77cf32e0f8e2025-08-20T02:40:29ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-07-011210.3389/fmed.2025.16189471618947The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathyLei Zhang0Lan Hu1Lan Hu2Lan Hu3Li Tan4Zhenjie Zhang5Mengying Chen6Wenbo Gan7Li Chen8Yan Zou9Shi Wang10Yu Pang11Zhenxin Fan12Junjie Liu13Guang’an People’s Hospital, Guan’an, ChinaDepartment of Emergency Medicine, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, ChinaInstitute of Disaster Medicine, Sichuan University, Chengdu, ChinaNursing Key Laboratory of Sichuan Province, Chengdu, ChinaKey Laboratory of Bioresources and Ecoenvironment (Ministry of Education), College of Life Sciences, Sichuan University, Chengdu, ChinaKey Laboratory of Bioresources and Ecoenvironment (Ministry of Education), College of Life Sciences, Sichuan University, Chengdu, ChinaGuang’an People’s Hospital, Guan’an, ChinaGuang’an People’s Hospital, Guan’an, ChinaGuang’an People’s Hospital, Guan’an, ChinaGuang’an People’s Hospital, Guan’an, ChinaGuang’an People’s Hospital, Guan’an, ChinaKey Laboratory of Bioresources and Ecoenvironment (Ministry of Education), College of Life Sciences, Sichuan University, Chengdu, ChinaKey Laboratory of Bioresources and Ecoenvironment (Ministry of Education), College of Life Sciences, Sichuan University, Chengdu, ChinaGuang’an People’s Hospital, Guan’an, ChinaIntroductionImmunoglobulin A nephropathy (IgAN) and membranous nephropathy (MN) are among the most common forms of primary glomerular diseases, with a rising global incidence. Despite their clinical importance, the underlying pathogenesis of these diseases and the development of reliable non-invasive diagnostic tools remain inadequately understood. Accumulating evidence suggests that gut microbiota and its associated metabolites may play a crucial role in the development of kidney diseases via the gut-kidney axis. However, comprehensive studies integrating both microbiome and metabolomic data in IgAN and MN are still limited.MethodsIn this study, we performed integrated metagenomic sequencing and untargeted metabolomic profiling to investigate alterations in gut microbial composition and systemic metabolic changes associated with IgAN and MN. Fecal samples were collected from 24 patients with IgAN, 20 patients with MN, and 17 healthy controls. Microbial diversity and composition were assessed using metagenomic analysis, while metabolic profiles were evaluated through untargeted LC -MS-based metabolomics. Multivariate statistical analyses and biomarker modeling were employed to identify discriminative features and evaluate diagnostic performance. Microbiota-metabolite correlation networks were constructed to explore potential mechanistic links.ResultsMetagenomic analysis showed that both the IgAN and MN groups had significantly reduced α-diversity. Although β-diversity analysis did not reveal significant differences between the three groups, the IgAN and MN groups exhibited higher sample dispersion than the control group. Notably, both IgAN and MN patients showed a decrease in the abundance of certain specific microbial taxa. A total of 34 and 28 differentially abundant microbial species were identified in IgAN and MN, respectively, compared to healthy controls, with 16 taxa consistently downregulated in both disease groups. Notably, Streptococcus oralis was significantly enriched in the MN group, while [Clostridium] innocuum was markedly depleted. Metabolomic profiling identified 307 and 209 differentially abundant metabolites in IgAN and MN, respectively. Dipeptides (e.g., prolylleucine) were consistently upregulated, while the levels of certain short-chain fatty acids (SCFA) were reduced. Multivariate biomarker models demonstrated excellent diagnostic performance, achieving area under the curve (AUC) of 0.919 (IgAN vs. control), 0.897 (MN vs. control) and 0.912 (IgAN vs. MN), surpassing individual metabolite markers.DiscussionOur findings highlight significant alterations in gut microbial composition and systemic metabolite profiles in both IgAN and MN patients compared to healthy individuals. The consistent reduction in microbial diversity and SCFA-producing taxa, along with characteristic changes in metabolic signatures, supports the involvement of the gut-kidney axis in disease pathogenesis. The diagnostic models developed in this study provide promising non-invasive biomarkers for distinguishing IgAN and MN with high accuracy. These results contribute novel insights into the microbe-metabolite interplay in glomerular diseases and offer potential targets for future diagnostic and therapeutic strategies.https://www.frontiersin.org/articles/10.3389/fmed.2025.1618947/fullIgA nephropathymembranous nephropathygut microbiotametabolomicsbiomarker
spellingShingle Lei Zhang
Lan Hu
Lan Hu
Lan Hu
Li Tan
Zhenjie Zhang
Mengying Chen
Wenbo Gan
Li Chen
Yan Zou
Shi Wang
Yu Pang
Zhenxin Fan
Junjie Liu
The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy
Frontiers in Medicine
IgA nephropathy
membranous nephropathy
gut microbiota
metabolomics
biomarker
title The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy
title_full The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy
title_fullStr The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy
title_full_unstemmed The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy
title_short The dysbiosis of gut microbiota and dysregulation of metabolites in IgA nephropathy and membranous nephropathy
title_sort dysbiosis of gut microbiota and dysregulation of metabolites in iga nephropathy and membranous nephropathy
topic IgA nephropathy
membranous nephropathy
gut microbiota
metabolomics
biomarker
url https://www.frontiersin.org/articles/10.3389/fmed.2025.1618947/full
work_keys_str_mv AT leizhang thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT lanhu thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT lanhu thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT lanhu thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT litan thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT zhenjiezhang thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT mengyingchen thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT wenbogan thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT lichen thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT yanzou thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT shiwang thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT yupang thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT zhenxinfan thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT junjieliu thedysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT leizhang dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT lanhu dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT lanhu dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT lanhu dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT litan dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT zhenjiezhang dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT mengyingchen dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT wenbogan dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT lichen dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT yanzou dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT shiwang dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT yupang dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT zhenxinfan dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy
AT junjieliu dysbiosisofgutmicrobiotaanddysregulationofmetabolitesiniganephropathyandmembranousnephropathy